Menu
Changes in the payer landscape are accelerating while pressure on prices continues to increase. These developments are mainly driven by the availability of more data to payers, competitive pressure and increasingly demanding HTA (Health Technology Assessment) agencies.
demanding agencies.
Innovative contracts refer to the use of non-traditional contracts (financial or performance-based models) to overcome access problems that cannot be solved by traditional pricing offers and ensure patient access to medicines.
The aim is to find the simplest solution that meets the payer’s needs while achieving the pricing and patient access ambitions.
Innovative contracts offer pharmaceutical companies the opportunity to link clinical outcomes to pricing agreements, highlighting the medio-economic performance of the innovation.
In short, outcome-based (performance-based) contracting is a contract that includes a penalty or reward based on the observed performance of the product.
At Access Focus, we are developing and adopting new and innovative methods, including new financial models, based on performance and outcomes, to ensure patient access to medicines.
By implementing the innovative contracting strategy, we can help maximize the value of the company’s product portfolio and create more space for dialogue about drug performance for patients.
< p>The Access Focus team will support you in the development of the innovative contracting strategy as well as its execution.</p >
In addition to supporting individual contract opportunities, the team works to develop relevant tools and models, including financial assessments and assessment of risks for pharmaceutical companies. These tools allow Market Access teams to identify and evaluate local innovative contract opportunities to ultimately obtain and expand access to innovative products.
The economic dimension has become of major interest to all players in the health system and is playing an increasingly important role in the evaluation of innovative strategies. It involves the use of complementary methodologies and various models. The integration of real-life patient experience data must now be considered in efficiency models.
Access Focus’ expert HEOR consultants have recognised experience in the economic evaluation of innovative health strategies (drugs, medical devices, vaccines, diagnostic or therapeutic interventions, e-health devices, new pathways, etc.).
Our services cover all innovative health strategies: drugs, medical devices, vaccines, diagnostic or therapeutic interventions, e-health devices, new pathways, etc.
Beyond economic analysis, our services focus on the evaluation of health outcomes as a whole.
Our services are aimed at multiple health stakeholders:
hospitals, manufacturers, start-ups, institutions and associations.
Medico-economic data can play a key role in raising awareness of a condition, making the case for a therapeutic area and justifying the value and reliability of your therapeutic solution.
In general, the most compelling uses of economic data combine both quantitative evidence (raw numbers and statistics from research, reports and surveys) and qualitative evidence (e.g. patient testimonials).
For example, some economic models have shown that investing in prevention, early detection, and better control and management is a very cost-effective way to improve public health that benefits both society and the economy. If not, it could lead to life-threatening complications, increase health-care costs related to complications, and undermine the ability of people with the disease to contribute to the economy.
The Access Focus team is at your disposal to answer all your questions and queries. Do not hesitate to contact us.
LPP Domaine Benddada Bt 06, N°1. Staoueli, Alger, Algérie